Profile data is unavailable for this security.
About the company
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.
- Revenue in USD (TTM)0.00
- Net income in USD-305.52m
- Incorporated2020
- Employees5.00
- LocationAeon Biopharma Inc5 Park Plaza, Suite 1750IRVINE 92614United StatesUSA
- Phone+1 (949) 354-6499
- Fax+1 (302) 655-5049
- Websitehttps://aeonbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurosense Therapeutics Ltd | 0.00 | -11.88m | 25.31m | 16.00 | -- | -- | -- | -- | -0.7299 | -0.7299 | 0.00 | -0.4488 | 0.00 | -- | -- | 0.00 | -350.36 | -- | -5,244.59 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
| Cue Biopharma Inc | 8.30m | -46.96m | 25.49m | 53.00 | -- | 1.18 | -- | 3.07 | -0.9743 | -0.9743 | 0.1718 | 0.4445 | 0.1437 | -- | 5.56 | 156,528.30 | -81.32 | -57.45 | -113.52 | -68.41 | -- | -- | -566.02 | -810.87 | -- | -- | 0.2242 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Nuo Therapeutics Inc | 1.03m | -2.69m | 25.63m | -- | -- | 41.78 | -- | 24.92 | -0.0622 | -0.0622 | 0.0237 | 0.0132 | 0.7332 | 0.954 | 4.06 | -- | -191.94 | -116.16 | -381.40 | -354.84 | 79.48 | 70.02 | -261.78 | -854.53 | 1.39 | -2,383.08 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
| Lipocine Inc | 4.80m | -8.49m | 25.88m | 17.00 | -- | 1.22 | -- | 5.39 | -1.60 | -1.60 | 0.9012 | 3.97 | 0.1794 | -- | 109.27 | 282,407.70 | -31.72 | -39.32 | -34.05 | -45.87 | -- | -- | -176.80 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Marker Therapeutics Inc | 3.73m | -10.31m | 26.23m | 8.00 | -- | 2.70 | -- | 7.04 | -1.16 | -1.17 | 0.4196 | 1.09 | 0.2217 | -- | 1.76 | 465,930.00 | -61.30 | -53.74 | -71.74 | -62.25 | -- | -- | -276.53 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Lisata Therapeutics Inc | 0.00 | -21.07m | 26.46m | 25.00 | -- | 0.6918 | -- | -- | -2.56 | -2.56 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -40.16 | -45.97 | -43.61 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| IGC Pharma Inc | 1.06m | -13.30m | 26.62m | 67.00 | -- | 3.38 | -- | 25.06 | -0.2104 | -0.2104 | 0.0167 | 0.1042 | 0.0809 | 0.2028 | 8.40 | 15,850.75 | -101.29 | -42.46 | -122.91 | -46.07 | 60.36 | 20.95 | -1,252.64 | -730.00 | 1.16 | -- | 0.0173 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
| Impact Biomedical Inc | 0.00 | -4.25m | 26.79m | 1.00 | -- | 1.15 | -- | -- | -0.3694 | -0.3694 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -9.59 | -- | -15.04 | -- | -- | -- | -- | -- | -- | -5.12 | 0.3377 | -- | -100.00 | -- | 38.51 | -- | -- | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -25.90m | 27.07m | 8.00 | -- | 1.38 | -- | -- | -4.97 | -4.97 | 0.00 | 2.30 | 0.00 | -- | -- | 0.00 | -89.41 | -95.57 | -117.09 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Aeon Biopharma Inc | 0.00 | -305.52m | 27.23m | 5.00 | -- | -- | -- | -- | -8.40 | -8.40 | 0.00 | -0.7144 | 0.00 | -- | -- | 0.00 | -6,646.10 | -- | -- | -- | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -2.01m | 28.12m | -- | -- | -- | -- | -- | -0.1562 | -0.1562 | 0.00 | -0.2067 | 0.00 | -- | -- | -- | -199.80 | -- | -- | -- | -- | -- | -- | -- | -- | -15.58 | -- | -- | -- | -- | -72.57 | -- | -- | -- |
| ImmuCell Corp | 23.22m | -4.05m | 28.20m | 74.00 | -- | 1.20 | -- | 1.21 | -0.521 | -0.521 | 2.99 | 2.99 | 0.5409 | 2.32 | 13.47 | 293,961.10 | -9.43 | -5.16 | -10.50 | -5.53 | 26.05 | 40.04 | -17.44 | -12.64 | 0.7668 | -7.43 | 0.3243 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Surrozen Inc | 0.00 | -53.45m | 28.44m | 42.00 | -- | 4.69 | -- | -- | -21.74 | -21.74 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -98.01 | -- | -110.62 | -- | -- | -- | -- | -- | -- | -2.05 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Aligos Therapeutics Inc | 7.97m | -75.74m | 29.21m | 68.00 | -- | 0.8543 | -- | 3.67 | -25.99 | -25.99 | 1.89 | 10.70 | 0.0741 | -- | -- | 120,712.10 | -70.47 | -51.20 | -92.27 | -59.73 | -- | -- | -950.61 | -1,399.21 | -- | -- | 0.0031 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| RenovoRx Inc | 0.00 | -8.11m | 29.26m | 8.00 | -- | 3.15 | -- | -- | -0.6059 | -0.6059 | 0.00 | 0.3868 | 0.00 | -- | -- | 0.00 | -88.58 | -- | -106.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
Data as of Sep 21 2024. Currency figures normalised to Aeon Biopharma Inc's reporting currency: US Dollar USD
13.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Polar Asset Management Partners, Inc.as of 30 Jun 2024 | 3.68m | 9.30% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 744.10k | 1.88% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 269.61k | 0.68% |
| Ikarian Capital LLCas of 30 Jun 2024 | 257.98k | 0.65% |
| Geode Capital Management LLCas of 30 Jun 2024 | 186.86k | 0.47% |
| Formidable Asset Management LLCas of 30 Jun 2024 | 113.64k | 0.29% |
| Davidson Kempner Capital Management LPas of 30 Jun 2024 | 90.05k | 0.23% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 60.95k | 0.15% |
| Boothbay Fund Management LLCas of 30 Jun 2024 | 55.06k | 0.14% |
| LMR Partners LLPas of 30 Jun 2024 | 54.96k | 0.14% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
